Table 3.
Patient demographics and baseline disease characteristics*
| Characteristic | Patients (N = 45) |
|---|---|
| Median (range) age, years | 70 (48–85) |
| 45–< 65, n (%) | 8 (17.8) |
| 65–< 75, n (%) | 21 (46.7) |
| ≥ 75, n (%) | 16 (35.6) |
| Sex, n (%) | |
| Male | 24 (53.3) |
| Female | 21 (46.7) |
| Race, n (%) | |
| White | 43 (95.6) |
| Black | 1 (2.2) |
| Other | 1 (2.2) |
| Median (range) height, cm | 168 (152–193) |
| Median (range) weight, kg | 74 (46–114) |
| Type of MF, n (%) | |
| PMF | 25 (55.6) |
| PPV-MF | 13 (28.9) |
| PET-MF | 7 (15.6) |
| Median (range) spleen volume,† cm3 | 1798.5 (763.2–6633.4) |
| Median (range) palpable spleen length below costal margin, cm | 13 (0–34) |
| Prior hydroxyurea use, n (%) | 29 (64.4) |
| ECOG performance status, n (%) | |
| 0 | 17 (37.8) |
| 1 | 20 (44.4) |
| 2 | 7 (15.6) |
| 3 | 1 (2.2) |
| DIPSS score, n (%) | |
| High risk (5–6) | 6 (13.3) |
| Intermediate-2 (3–4) | 7 (15.6) |
| Intermediate-1 (1–2) | 31 (68.9) |
| Low (0) | 1 (2.2) |
| Transfusion status, n (%) | |
| Independent | 30 (66.7) |
| Dependent | 15 (33.3) |
| JAK2 mutation status, n‡ (%) | |
| Present | 29 (64.4) |
| Absent | 15 (33.3) |
| Median (range) V617F at baseline for patients with JAK2 mutation, %§ | 77 (1–96) |
DIPSS Dynamic International Prognostic Scoring System, ECOG Eastern Cooperative Oncology Group, JAK Janus kinase, MF myelofibrosis, PET-MF post-essential thrombocythemia myelofibrosis, PMF primary myelofibrosis, PPV-MF post-polycythemia vera myelofibrosis
*Intent-to-treat population
†n = 42
‡One patient had a missing baseline value for JAK mutation status
§n = 29